Want to see IN:PAR full AI Analyst Report?
Top Page
Par Drugs and Chemicals Limited
(PAR)
Select Model
Select Model
Rating:81Outperform
Price Target:
₹108.00
▲(7.00% Upside)
Action:Reiterated
Date:07/18/26
The score is driven primarily by strong financial quality—especially a zero-debt balance sheet—alongside solid profitability. Technicals also support the rating, with the stock in an uptrend above major moving averages and positive momentum signals. Valuation is moderately favorable due to a low P/E, though the lack of dividend yield data and some variability in growth, margins, and cash conversion temper the overall score.
Positive Factors
Balance sheet strength
A zero-debt balance sheet materially lowers financial risk and preserves flexibility for multi‑year investment, M&A, or R&D without refinancing needs. This structural strength improves resilience in downturns and supports durable capital allocation decisions over the next 2–6 months and beyond.
Negative Factors
Inconsistent revenue growth
Irregular top-line growth reduces predictability for capacity planning and long-term investment. Variability across years can signal reliance on episodic product cycles or uneven market penetration, making it harder to scale operations sustainably and judge multi‑period demand trends.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A zero-debt balance sheet materially lowers financial risk and preserves flexibility for multi‑year investment, M&A, or R&D without refinancing needs. This structural strength improves resilience in downturns and supports durable capital allocation decisions over the next 2–6 months and beyond.
Read all positive factors
Par Drugs and Chemicals Limited (PAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.21B
Dividend YieldN/A
Average Volume (3M)31.06K
Price to Earnings (P/E)9.3
Beta (1Y)1.06
Revenue Growth2.66%
EPS Growth-1.90%
CountryIN
Employees122
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)10.65
Shares Outstanding12,304,636
10 Day Avg. Volume60,109
30 Day Avg. Volume31,062
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)0.86
Price to Sales (P/S)0.93
P/FCF Ratio6.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Par Drugs and Chemicals Limited Business Overview & Revenue Model
Company Description
Par Drugs and Chemicals Limited is an Indian enterprise that focuses on the creation, production, and sale of active pharmaceutical ingredients (APIs) and specialized chemicals. Its comprehensive product line features a diverse array of compounds,...
How the Company Makes Money
null...
Par Drugs and Chemicals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
77
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.04B | 1.01B | 956.40M | 950.95M | 746.15M |
| Gross Profit | 504.71M | 628.43M | 609.88M | 286.90M | 243.36M |
| EBITDA | 211.32M | 195.01M | 229.53M | 184.46M | 163.61M |
| Net Income | 131.09M | 133.58M | 145.01M | 113.34M | 92.13M |
Balance Sheet | |||||
| Total Assets | 1.29B | 1.19B | 1.02B | 888.68M | 786.90M |
| Cash, Cash Equivalents and Short-Term Investments | 418.43M | 275.77M | 366.54M | 222.43M | 162.06M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 172.28M | 204.15M | 159.79M | 176.30M | 188.13M |
| Stockholders Equity | 1.12B | 989.75M | 856.32M | 712.38M | 598.77M |
Cash Flow | |||||
| Free Cash Flow | 144.71M | 149.34M | 141.69M | 57.44M | 44.13M |
| Operating Cash Flow | 164.32M | 161.60M | 202.49M | 133.77M | 76.15M |
| Investing Cash Flow | -21.66M | -252.37M | -58.38M | -73.38M | -30.18M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | -24.00K | -95.54M |
Par Drugs and Chemicals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.21B | 9.31 | ― | ― | 2.66% | -1.90% | |
65 Neutral | ₹1.79B | 7.19 | ― | ― | 3.85% | ― | |
61 Neutral | ₹1.43B | 10.04 | ― | ― | -5.91% | -26.95% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | ₹1.42B | 22.59 | ― | 1.38% | 2.83% | -26.18% | |
51 Neutral | ₹524.83M | 19.21 | ― | ― | -14.99% | 399.30% | |
39 Underperform | ₹419.54M | -0.24 | ― | ― | -39.80% | -452.04% |
* General Sector Average
IN:PAR
Par Drugs and Chemicals Limited
98.40
-4.59
-4.46%
IN:ALPA
Alpa Laboratories Limited
67.76
-24.79
-26.79%
IN:BALPHARMA
Bal Pharma Limited
89.38
-4.58
-4.87%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
32.25
-11.25
-25.86%
IN:BROOKS
Brooks Laboratories Limited
60.85
-92.50
-60.32%
IN:VIVIMEDLAB
Vivimed Labs Limited
5.06
0.16
3.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.